1) Strong Financial Performance
- Revenues for Q2 2026 reached $872 million, a 13% organic growth YoY.
- Adjusted EPS was $2.37, reflecting a 29% increase compared to the previous year.
- Proprietary Products segment grew 15.5% organically, with HVP Components driving 18.4% growth.
- The company raised its full-year guidance, now expecting organic revenue growth of 10% to 11% and adjusted EPS between $8.85 to $9.05.

2) Segment Highlights and Growth Drivers
- Proprietary Products: Continued strong performance, particularly in Biologics and Biosimilars, with 29% growth in the Biologics market.
- HVP Components: Now accounts for 49% of total revenues, driven by GLP-1s and HVP upgrades.
- Standard Products: Slight growth of 0.7%, serving as a funnel for future upgrades to HVP Components.
- HVP Delivery Devices: Grew 29% organically, with strong demand for SmartDose and other devices.

3) Operational Challenges and Cyber Incident Recovery
- The company faced challenges due to a cyber incident in May, impacting the West Vantage segment, which grew only 0.8% organically.
- The incident resulted in a mid-single-digit impact on growth, but recovery efforts were noted as successful, contributing to overall strong Q2 results.
- Operational excellence initiatives helped mitigate the impact of the cyber incident.

4) Guidance and Future Outlook
- Full-year revenue guidance increased to $3.345 billion to $3.380 billion, with reported growth now projected at 8.8% to 10%.
- Q3 revenue guidance is set between $820 million to $835 million, reflecting a 1.9% to 3.8% increase.
- Continued strong growth expected in GLP-1s and non-GLP-1 HVP Components, with both anticipated to grow in the high teens.
- Margin expansion of over 200 basis points is expected for the year, despite inflationary pressures.

5) Leadership Transition and Strategic Focus
- Eric Green will transition leadership to Michel Lagarde on August 31, marking a significant change in the company's direction.
- The company remains focused on its three key growth drivers: Biologics, GLP-1s, and Annex 1 upgrades.
- Further details on the impact of leadership change and long-term strategic initiatives were not fully covered in the call.

Bottom line: West Pharmaceutical Services demonstrated robust financial performance in Q2 2026, driven by strong growth in proprietary products and strategic initiatives. The company is well-positioned to capitalize on long-term trends in the Biologics and GLP-1 markets, despite operational challenges from a recent cyber incident. The leadership transition may bring new perspectives, but the existing growth strategy remains intact, making it a favorable outlook for shareholders.